VDPHL01 + Placebo
Phase 2/3Active 0 watching 0 views this week📈 Rising
60
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Androgenetic Alopecia
Conditions
Androgenetic Alopecia, AGA, Male Pattern Baldness
Trial Timeline
Nov 6, 2024 → Sep 1, 2026
NCT ID
NCT06724614About VDPHL01 + Placebo
VDPHL01 + Placebo is a phase 2/3 stage product being developed by Veradermics for Androgenetic Alopecia. The current trial status is active. This product is registered under clinical trial identifier NCT06724614. Target conditions include Androgenetic Alopecia, AGA, Male Pattern Baldness.
Hype Score Breakdown
Clinical
22
Activity
15
Company
5
Novelty
7
Community
8
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06972264 | Phase 3 | Active |
| NCT06724614 | Phase 2/3 | Active |
Competing Products
12 competing products in Androgenetic Alopecia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| minoxidil | Johnson & Johnson | Phase 3 | 77 |
| Minoxidil + vehicle of 5% Minoxidil topical foam | Johnson & Johnson | Phase 2 | 52 |
| 5% Minoxidil Topical Foam + Vehicle Topical Foam | Johnson & Johnson | Phase 3 | 77 |
| Cyproterone Acetate (Androcur, BAY94-8367) | Bayer | Pre-clinical | 20 |
| Clascoterone 5% solution + Vehicle solution | ICON plc. | Phase 3 | 74 |
| Clascoterone 5% solution + Vehicle solution | ICON plc. | Phase 3 | 74 |
| VDPHL01 | Veradermics | Phase 2 | 47 |
| VDPHL01 QD + Placebo + VDPHL01 BID + Placebo | Veradermics | Phase 3 | 72 |
| VDPHL01 + Placebo | Veradermics | Phase 3 | 72 |
| MK0906, finasteride / Duration of Treatment : 48 Weeks + Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks | Organon | Phase 3 | 72 |
| ABS-201 IV Single Dose + Placebo IV + ABS-201 SC Multiple Doses + Placebo SC Injection | AbSci | Phase 1/2 | 33 |
| ATI-50002 | Aclaris Therapeutics | Phase 2 | 44 |